{"id":"ftc-tdf-prep","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":null,"effect":"Renal function decline (TDF-related)"},{"rate":null,"effect":"Bone mineral density loss (TDF-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) are nucleoside/nucleotide reverse transcriptase inhibitors that work synergistically to suppress HIV replication. When taken as pre-exposure prophylaxis (PrEP), they maintain sufficient drug levels in blood and tissues to block HIV infection at the point of viral entry and early replication, reducing transmission risk in high-risk individuals.","oneSentence":"FTC-TDF PrEP blocks reverse transcriptase in HIV, preventing the virus from converting its RNA genome into DNA and integrating into host cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:17.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV pre-exposure prophylaxis (PrEP) in high-risk individuals"}]},"trialDetails":[{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":"Contact With or Exposure to Human Immunodeficiency Virus","enrollment":1500},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT07473778","phase":"","title":"Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention","status":"NOT_YET_RECRUITING","sponsor":"Gilead Sciences","startDate":"2026-03","conditions":"HIV Infections","enrollment":3000},{"nctId":"NCT07462611","phase":"NA","title":"HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department Study","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-03-30","conditions":"HIV Pre-exposure Prophylaxis, PrEP","enrollment":250},{"nctId":"NCT07288190","phase":"PHASE2","title":"Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR","status":"NOT_YET_RECRUITING","sponsor":"HIV Prevention Trials Network","startDate":"2026-05-15","conditions":"Pregnancy, HIV Infections","enrollment":300},{"nctId":"NCT06435026","phase":"PHASE2","title":"Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-06-18","conditions":"HIV, Prevention, Pregnancy","enrollment":54},{"nctId":"NCT07349758","phase":"PHASE1","title":"Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-01-06","conditions":"Healthy Volunteer, HIV Prevention","enrollment":24},{"nctId":"NCT04898699","phase":"EARLY_PHASE1","title":"IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya","status":"COMPLETED","sponsor":"Columbia University","startDate":"2021-11-24","conditions":"HIV","enrollment":120},{"nctId":"NCT07390409","phase":"","title":"ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.","status":"NOT_YET_RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2026-01-29","conditions":"HIV","enrollment":3700},{"nctId":"NCT04644029","phase":"PHASE3","title":"Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-24","conditions":"HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis","enrollment":730},{"nctId":"NCT06132386","phase":"","title":"Analysis of Cellular Kinases and Aging in PBMCs and Colorectal Tissue","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2023-08-07","conditions":"HIV Infections, Aging","enrollment":21},{"nctId":"NCT04925752","phase":"PHASE3","title":"Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-06-28","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":3292},{"nctId":"NCT04782180","phase":"PHASE4","title":"PrEP at a Syringe Services Program","status":"COMPLETED","sponsor":"University of Miami","startDate":"2022-02-01","conditions":"Hiv, Substance Use Disorders","enrollment":90},{"nctId":"NCT04222504","phase":"NA","title":"Community-based Venues for Delivery of Healthcare Services: Proof of Concept Pilot","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-02-08","conditions":"Pre-Exposure Prophylaxis, STI, Contraceptive Usage","enrollment":500},{"nctId":"NCT04742491","phase":"PHASE2, PHASE3","title":"Pre-Exposure Prophylaxis for Transgender Women in the US and South America","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2021-03-26","conditions":"HIV Prevention","enrollment":304},{"nctId":"NCT06766331","phase":"NA","title":"Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2028-04-03","conditions":"Opioid Use Disorder, HIV, Hepatitis C Virus","enrollment":60},{"nctId":"NCT07279129","phase":"PHASE1","title":"Decision Support Tool to Integrate PrEP Into Emergency Departments","status":"NOT_YET_RECRUITING","sponsor":"George Washington University","startDate":"2027-01-15","conditions":"HIV","enrollment":120},{"nctId":"NCT04429971","phase":"NA","title":"Pre-Exposure Prophylaxis in the Emergency Department","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2020-03-18","conditions":"HIV/AIDS, PrEP","enrollment":26},{"nctId":"NCT05528653","phase":"PHASE4","title":"Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: \"e-PrEP\"","status":"COMPLETED","sponsor":"Vivent Health","startDate":"2022-07-19","conditions":"HIV Prevention","enrollment":75},{"nctId":"NCT05095818","phase":"NA","title":"Impact of Nursing Involvement on Implementation of HIV Prevention Services","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-04-01","conditions":"Pre-Exposure Prophylaxis (PrEP)","enrollment":440},{"nctId":"NCT03512418","phase":"PHASE3","title":"Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-06-20","conditions":"HIV Infections, Substance Use Disorders","enrollment":30},{"nctId":"NCT04666792","phase":"PHASE4","title":"PrEParing Family Planning Clinics to Streamline Integration of HIV Prevention Services for Young Women in Kenya","status":"COMPLETED","sponsor":"University of Washington","startDate":"2021-03-01","conditions":"HIV Infections, Contraception, STI","enrollment":25457},{"nctId":"NCT06513312","phase":"PHASE2","title":"Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-07","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":268},{"nctId":"NCT04760691","phase":"PHASE1","title":"Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-03-01","conditions":"Hiv, Prophylaxis, Transgender","enrollment":13},{"nctId":"NCT04331704","phase":"PHASE4","title":"ANCHORS Alcohol & Sexual Health Study: UH3 Project","status":"RECRUITING","sponsor":"University of Florida","startDate":"2021-01-12","conditions":"Alcohol Use, Unspecified, Substance Use, Sex Behavior","enrollment":88},{"nctId":"NCT03771638","phase":"PHASE4","title":"DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men","status":"COMPLETED","sponsor":"Public Health Foundation Enterprises, Inc.","startDate":"2019-02-01","conditions":"Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis","enrollment":100},{"nctId":"NCT05813964","phase":"PHASE3","title":"Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-06-05","conditions":"HIV/AIDS","enrollment":524},{"nctId":"NCT02732730","phase":"PHASE4","title":"Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2016-10-12","conditions":"HIV","enrollment":451},{"nctId":"NCT07006246","phase":"PHASE4","title":"Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Professor Francois Venter","startDate":"2023-05-19","conditions":"HIV Infection","enrollment":1900},{"nctId":"NCT05072093","phase":"PHASE4","title":"Parrying the Pitfalls of PrEP: Project PEACH","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-11-20","conditions":"HIV, STI","enrollment":240},{"nctId":"NCT04692077","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-19","conditions":"HIV Infections","enrollment":9},{"nctId":"NCT05378399","phase":"PHASE3","title":"SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-12-20","conditions":"HIV Infections, Substance Use, Adherence, Medication","enrollment":40},{"nctId":"NCT01327651","phase":"PHASE2","title":"The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2011-08","conditions":"HIV Infections","enrollment":622},{"nctId":"NCT06566430","phase":"NA","title":"PrEP My Way: a Hybrid Type 1 Clinical Effectiveness-implementation Trial to Promote PrEP Persistence Among Young Kenyan Women","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-03-03","conditions":"HIV/AIDS","enrollment":500},{"nctId":"NCT06158126","phase":"PHASE4","title":"UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-04-17","conditions":"Pre-exposure Prophylaxis, HIV Prevention, Pregnancy Related","enrollment":621},{"nctId":"NCT03386578","phase":"PHASE2","title":"Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-03","conditions":"HIV Infections","enrollment":780},{"nctId":"NCT05755204","phase":"","title":"A Pharmacist-run PrEP Program for Women","status":"TERMINATED","sponsor":"Orlando Immunology Center","startDate":"2023-06-21","conditions":"HIV Prevention","enrollment":2},{"nctId":"NCT06807736","phase":"","title":"PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.","status":"RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2024-02-13","conditions":"HIV Infection, Sexual and Reproductive Health","enrollment":1800},{"nctId":"NCT04066881","phase":"PHASE2","title":"A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2020-12-15","conditions":"HIV Infections","enrollment":1512},{"nctId":"NCT04652700","phase":"PHASE3","title":"Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-15","conditions":"HIV Preexposure Prophylaxis","enrollment":494},{"nctId":"NCT02437981","phase":"","title":"Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous Clinic","status":"ENROLLING_BY_INVITATION","sponsor":"Thai Red Cross AIDS Research Centre","startDate":"2014-12","conditions":"HIV Prevention","enrollment":20000},{"nctId":"NCT04590417","phase":"NA","title":"Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thai Red Cross AIDS Research Centre","startDate":"2022-01-24","conditions":"Drug Interaction","enrollment":20},{"nctId":"NCT04593680","phase":"NA","title":"Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thai Red Cross AIDS Research Centre","startDate":"2022-01-24","conditions":"Drug Interaction","enrollment":20},{"nctId":"NCT03902418","phase":"","title":"Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2019-07-01","conditions":"HIV-I Infection","enrollment":1195},{"nctId":"NCT06631365","phase":"PHASE2","title":"PrEPsmart 2-1-1 Pilot","status":"RECRUITING","sponsor":"Public Health Foundation Enterprises, Inc.","startDate":"2023-10-02","conditions":"HIV-1-infection","enrollment":60},{"nctId":"NCT05592613","phase":"PHASE3","title":"Next Generation Ingestible Sensors for Medication Adherence Measurement","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2023-02-06","conditions":"HIV Infection, Adherence, Medication, Adherence, Treatment","enrollment":15},{"nctId":"NCT04298697","phase":"PHASE4","title":"Biomarkers for Event-driven PrEP Adherence","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-02-28","conditions":"Human Immunodeficiency Virus","enrollment":43},{"nctId":"NCT04937881","phase":"PHASE3","title":"PK of TAF and TDF for PrEP in Pregnant and Postpartum Women","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-06-13","conditions":"Hiv","enrollment":39},{"nctId":"NCT02844634","phase":"PHASE4","title":"Tenofovir/Emtricitabine With Doxycycline for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative MSM","status":"COMPLETED","sponsor":"British Columbia Centre for Disease Control","startDate":"2018-05-15","conditions":"HIV, Syphilis","enrollment":52},{"nctId":"NCT04597424","phase":"PHASE3","title":"Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-01-19","conditions":"Unsafe Sex, Risk-Taking","enrollment":556},{"nctId":"NCT05458765","phase":"PHASE2","title":"Project Engage: Oral PrEP Acceptability","status":"COMPLETED","sponsor":"Eastern Virginia Medical School","startDate":"2022-06-21","conditions":"Acceptability of Health Care, Adherence, Medication","enrollment":330},{"nctId":"NCT06138600","phase":"PHASE3","title":"Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2023-11-01","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT03464266","phase":"PHASE4","title":"The Kampala Women's Bone Study","status":"COMPLETED","sponsor":"University of Washington","startDate":"2018-05-15","conditions":"Bone Demineralization, Hypoestrogenism, Subclinical Kidney Injury","enrollment":500},{"nctId":"NCT02074891","phase":"","title":"Sustainable Healthcenter Implementation PrEP Pilot Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-10","conditions":"HIV Chemoprophylaxis, HIV Preexposure Prophylaxis","enrollment":1420},{"nctId":"NCT05746065","phase":"","title":"A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African Women","status":"COMPLETED","sponsor":"University of Washington","startDate":"2022-08-01","conditions":"HIV Infections","enrollment":3087},{"nctId":"NCT05159531","phase":"PHASE4","title":"Virtual PrEP: Rendering PrEP Delivery More Efficient","status":"TERMINATED","sponsor":"Unity Health Toronto","startDate":"2023-05-01","conditions":"HIV Infections","enrollment":2},{"nctId":"NCT06250504","phase":"PHASE3","title":"Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT","status":"RECRUITING","sponsor":"Africa Health Research Institute","startDate":"2024-02-27","conditions":"HIV Infections","enrollment":2000},{"nctId":"NCT04077151","phase":"NA","title":"Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - Demonstration Project","status":"COMPLETED","sponsor":"Hektoen Institute for Medical Research","startDate":"2022-03-14","conditions":"HIV/AIDS, Gender, Behavior and Behavior Mechanisms","enrollment":51},{"nctId":"NCT04077138","phase":"","title":"Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - Intervention Development","status":"COMPLETED","sponsor":"Hektoen Institute for Medical Research","startDate":"2019-01-01","conditions":"HIV/AIDS, Gender, Behavior and Behavior Mechanisms","enrollment":80},{"nctId":"NCT03652623","phase":"PHASE1, PHASE2","title":"Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study","status":"COMPLETED","sponsor":"Hektoen Institute for Medical Research","startDate":"2018-07-23","conditions":"HIV/AIDS, Gender, Behavior and Behavior Mechanisms","enrollment":49},{"nctId":"NCT05690815","phase":"","title":"Express Testing and Same-day Initiation of PrEP Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"HQ Toronto","startDate":"2023-01-24","conditions":"HIV Prevention","enrollment":816},{"nctId":"NCT06273943","phase":"PHASE3","title":"Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-01","conditions":"Prevention","enrollment":322},{"nctId":"NCT03995862","phase":"","title":"Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region","status":"COMPLETED","sponsor":"Centre Hospitalier Annecy Genevois","startDate":"2019-05-29","conditions":"Pre-Exposure Prophylaxis, HIV Seronegativity, Drug Combination","enrollment":242},{"nctId":"NCT04367688","phase":"","title":"HIV Pre-exposure Prophylaxis Implementation Hong Kong Study","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2020-03-01","conditions":"HIV Infections","enrollment":339},{"nctId":"NCT04778527","phase":"NA","title":"A Crossover Adherence and Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention","status":"UNKNOWN","sponsor":"Population Council","startDate":"2022-09-13","conditions":"HIV Infections","enrollment":96},{"nctId":"NCT04778514","phase":"NA","title":"A Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention","status":"COMPLETED","sponsor":"Population Council","startDate":"2022-12-07","conditions":"HIV Infections, Contraception","enrollment":30},{"nctId":"NCT03459157","phase":"NA","title":"Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-11-20","conditions":"HIV/AIDS","enrollment":649},{"nctId":"NCT04870671","phase":"EARLY_PHASE1","title":"Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor","status":"COMPLETED","sponsor":"Eastern Virginia Medical School","startDate":"2021-03-25","conditions":"HIV/AIDS, Adherence, Medication, Drug Use","enrollment":14},{"nctId":"NCT03826199","phase":"PHASE4","title":"Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2019-08-23","conditions":"Hiv","enrollment":200},{"nctId":"NCT06133686","phase":"PHASE3","title":"Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa","status":"NOT_YET_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2024-04-01","conditions":"HIV","enrollment":400},{"nctId":"NCT03255915","phase":"EARLY_PHASE1","title":"PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)","status":"UNKNOWN","sponsor":"Oak Crest Institute of Science","startDate":"2018-09-20","conditions":"HIV Prevention","enrollment":15},{"nctId":"NCT03194308","phase":"PHASE4","title":"Safer Conception for Women - Understanding Use of Periconception PrEP","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-11-13","conditions":"HIV Prevention, Conception","enrollment":330},{"nctId":"NCT05307991","phase":"","title":"Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-03-09","conditions":"HIV Infections, Sexually Transmitted Diseases, Blood-Borne Infections","enrollment":249},{"nctId":"NCT05492565","phase":"","title":"Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis","status":"ENROLLING_BY_INVITATION","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2020-01-01","conditions":"HIV Infection Primary, Hepatitis, Viral, Human, Sexually Transmitted Infections, Excluding HIV and Hepatitis","enrollment":500},{"nctId":"NCT03058835","phase":"PHASE4","title":"IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project","status":"UNKNOWN","sponsor":"Rutgers, The State University of New Jersey","startDate":"2016-09","conditions":"PrEP Adherence Monitoring","enrollment":125},{"nctId":"NCT06030557","phase":"","title":"PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP)","status":"UNKNOWN","sponsor":"CAN Community Health","startDate":"2023-04-16","conditions":"Hiv Prevention, Pre-Exposure Prophylaxis (PrEP)","enrollment":210},{"nctId":"NCT04902820","phase":"NA","title":"PrEPTECH Phase 2 Study of a PrEP Telehealth Intervention","status":"COMPLETED","sponsor":"ETR Associates","startDate":"2022-02-12","conditions":"Pre-Exposure Prophylaxis, HIV, Telemedicine","enrollment":229},{"nctId":"NCT02213328","phase":"PHASE2","title":"Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-04","conditions":"HIV Infections","enrollment":148},{"nctId":"NCT04616963","phase":"PHASE4","title":"Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2019-10-24","conditions":"Hiv, Hormone Therapy","enrollment":64},{"nctId":"NCT05108935","phase":"NA","title":"Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP","status":"COMPLETED","sponsor":"Duke University","startDate":"2022-02-17","conditions":"Opioid Use, Opioid Use Disorder, Risk Reduction","enrollment":17},{"nctId":"NCT04092114","phase":"NA","title":"CHARISMA Expansion Study","status":"COMPLETED","sponsor":"RTI International","startDate":"2018-10-15","conditions":"Relationship Dynamics, Pre-exposure Prophylaxis (PrEP) Adherence","enrollment":407},{"nctId":"NCT03842436","phase":"PHASE4","title":"Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-10-01","conditions":"HIV/AIDS, Substance Use Disorders, Adherence, Medication","enrollment":16},{"nctId":"NCT03227731","phase":"PHASE2, PHASE3","title":"Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women","status":"COMPLETED","sponsor":"University of KwaZulu","startDate":"2017-09-28","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT03988387","phase":"NA","title":"IPREP Study #2: Evaluating Enhanced PrEP Packages for Young Female Sex Workers in Kisumu, Kenya","status":"COMPLETED","sponsor":"Columbia University","startDate":"2019-10-31","conditions":"HIV","enrollment":200},{"nctId":"NCT03986970","phase":"PHASE2","title":"The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2019-11-11","conditions":"HIV/AIDS","enrollment":72},{"nctId":"NCT03113123","phase":"NA","title":"Prevention of HIV in \"Île-de-France\"","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-05-03","conditions":"HIV Infections","enrollment":3257},{"nctId":"NCT04329442","phase":"NA","title":"Accelerated PrEP Access for Black MSM and TW","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2020-04-01","conditions":"HIV/AIDS","enrollment":""},{"nctId":"NCT04318210","phase":"NA","title":"Open Label Extension (OLE) of the TDF2 Study, Botswana","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-10","conditions":"HIV Infections","enrollment":229},{"nctId":"NCT03834909","phase":"PHASE1","title":"Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2022-04","conditions":"Pregnancy, HIV-1-infection","enrollment":""},{"nctId":"NCT04039217","phase":"PHASE4","title":"Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-09-30","conditions":"ART, HIV","enrollment":20},{"nctId":"NCT01571128","phase":"NA","title":"Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)","status":"COMPLETED","sponsor":"New York University","startDate":"2014-11","conditions":"HIV, Adolescent Behavior, Gender","enrollment":1215},{"nctId":"NCT03490058","phase":"","title":"The Prevention Options for Women Evaluation Research (POWER) Cohort","status":"COMPLETED","sponsor":"University of Washington","startDate":"2017-06-14","conditions":"HIV/AIDS","enrollment":2255},{"nctId":"NCT03586128","phase":"","title":"Partners PrEP Program","status":"COMPLETED","sponsor":"University of Washington","startDate":"2018-06-08","conditions":"HIV Infections","enrollment":1381},{"nctId":"NCT01632995","phase":"NA","title":"Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-10","conditions":"HIV Infections","enrollment":557},{"nctId":"NCT01505114","phase":"PHASE2","title":"Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-06","conditions":"HIV Infection","enrollment":594},{"nctId":"NCT03387462","phase":"PHASE4","title":"DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence","status":"COMPLETED","sponsor":"Public Health Foundation Enterprises, Inc.","startDate":"2018-02-28","conditions":"Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis","enrollment":20},{"nctId":"NCT03052010","phase":"PHASE4","title":"The Partners Scale-Up Project","status":"COMPLETED","sponsor":"University of Washington","startDate":"2017-02-06","conditions":"HIV-1-infection","enrollment":4898},{"nctId":"NCT03350672","phase":"PHASE4","title":"Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide","status":"COMPLETED","sponsor":"Philadelphia Fight","startDate":"2017-11-16","conditions":"Hiv","enrollment":37},{"nctId":"NCT02776748","phase":"PHASE2, PHASE3","title":"PrEP in Breastfeeding Study","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-01","conditions":"HIV Pre-exposure Prophylaxis During Breastfeeding","enrollment":50},{"nctId":"NCT01906255","phase":"","title":"Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10-07","conditions":"HIV","enrollment":10577}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"FTC-TDF PrEP","genericName":"FTC-TDF PrEP","companyName":"University of Washington","companyId":"university-of-washington","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FTC-TDF PrEP blocks reverse transcriptase in HIV, preventing the virus from converting its RNA genome into DNA and integrating into host cells. Used for HIV pre-exposure prophylaxis (PrEP) in high-risk individuals.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}